LXEO
What one share of Lexeo Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.
Lexeo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.15 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.16 |
| Cash and investments | $1.18 |
| Book value | $2.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.40 | −$36.36 | $0.41 | −$33.88 | — | −$70.28 |
| 2023 | — | −$12.40 | $0.02 | −$11.13 | — | — |
| 2024 | — | −$3.09 | $0.02 | −$2.57 | — | $3.53 |
| 2025 | — | −$1.86 | $0.01 | −$1.84 | — | $3.38 |